CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of endometrial cancer.
  
  LEARNING OBJECTIVES

  • Evaluate the importance of microsatellite instability (MSI) and DNA mismatch repair (MMR) deficiency assessment for patients with endometrial cancer, and adapt current testing practices to optimally identify genetic abnormalities.
  • Review the benefits observed with anti-PD-1/PD-L1 antibodies for MSI-high or MMR-deficient endometrial cancer, and appropriately integrate these agents into the care of patients.
  • Recognize the biologic rationale for and available data with the combination of anti-PD-1/PD-L1 antibodies with agents targeting the VEGF pathway, and select patients with metastatic endometrial cancer for this novel approach.
  • Design and implement a plan of care to manage side effects and toxicities associated with immune checkpoint inhibitor-based therapies for endometrial cancer in order to support quality of life and continuation of treatment.
  • Describe the scientific justification for and published research data with novel agents and strategies under investigation for endometrial cancer, and effectively prioritize clinical trial opportunities for eligible patients.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY —The following faculty and moderator reported relevant financial relationships with ineligible entities:
  
  Robert L Coleman, MD
  Chief Medical Officer
  Sarah Cannon Research Institute (SCRI)
  Gynecologic Oncology
  The Woodlands, Texas
  
  Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, GSK, ImmunoGen Inc, Merck, Myriad Genetic Laboratories Inc, Seagen Inc; Contracted Research: Clovis Oncology, Genentech, a member of the Roche Group, GSK, ImmunoGen Inc, Merck, Seagen Inc; Data and Safety Monitoring Board/Committee: Eisai Inc.
  
  Matthew A Powell, MD
  Professor, Department of Obstetrics and Gynecology
  Washington University School of Medicine
  St Louis, Missouri
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, GSK, Merck, Roche Laboratories Inc, Seagen Inc; Contracted Research: GSK.
  
  Brian M Slomovitz, MD
  Professor, OB-GYN, Florida International University
  Director, Gynecologic Oncology
  Co-Chair, Cancer Research Committee
  Mount Sinai Medical Center
  Miami, Florida
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Clovis Oncology, EQRx, Genentech, a member of the Roche Group, Genmab US Inc, GSK, Incyte Corporation, Lilly, Merck, Novartis, Seagen Inc.
  
  MODERATOR
  
  Shannon N Westin, MD, MPH
  Professor
  Director, Early Drug Development
  Department of Gynecologic Oncology and Reproductive Medicine
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Consulting Agreements: Agenus Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, EQRx, Genentech, a member of the Roche Group, GSK, ImmunoGen Inc, Lilly, Merck, Mereo BioPharma, Mersana Therapeutics Inc, NGM Bio, Nuvectis Pharma Inc, Seagen Inc, Vincerx Pharma, Zentalis Pharmaceuticals; Contracted Research: AstraZeneca Pharmaceuticals LP, Avenge Bio, Bio-Path Holdings, Clovis Oncology, Genentech, a member of the Roche Group, GSK, Mereo BioPharma, OncXerna Therapeutics Inc, Zentalis Pharmaceuticals.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GSK, and Karyopharm Therapeutics.
  
  Release date: April 2023
  Expiration date: April 2024